<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287624</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2010-04</org_study_id>
    <secondary_id>CBCSG 006</secondary_id>
    <nct_id>NCT01287624</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)</brief_title>
  <acronym>TNBC</acronym>
  <official_title>A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-labeled, randomized phase III clinical trial
      comparing overall response rate (ORR), progression free survival (PFS), overall survival (OS)
      and toxicity obtained with gemcitabine cisplatin combination (GP) versus gemcitabine
      paclitaxel combination (GT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The previous phase II study showed that gemcitabine and cisplatin combination (GP) is an
      effective regimen in triple negative breast cancer (TNBC). The potential therapeutic effects
      of GP in advanced TNBC deserve further evaluation yet. Eligible patients are randomly
      assigned to receive either GP or GT regimen to verify the hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (Progression Free Survival)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP (gemcitabine and cisplatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine, Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GT (gemcitabine and paclitaxel combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine,cisplatin</intervention_name>
    <description>Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1</description>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
    <other_name>experimental arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Paclitaxel</intervention_name>
    <description>Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1</description>
    <arm_group_label>Gemcitabine, Paclitaxel</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 and 70 years old

          2. Histological proven unresectable recurrent or advanced breast cancer

          3. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human
             epithelial receptor-2 (HER2) by immunohistochemistry (IHC) test. For patients with ER
             negative, PR negative, Her2 two plus, a negative Her2 gene amplification should be
             verified with FISH test. Her2 one plus may consider FISH verification.

          4. No prior chemotherapy for metastatic breast cancer. Prior use of taxanes in the
             adjuvant/neoadjuvant setting is acceptable if completed 6 months prior to enrollment

          5. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST)

          6. Performance status not more than 1

          7. All patients enrolled are required to have adequate hematologic, hepatic, and renal
             function

          8. Life expectancy greater than 12 weeks

          9. No serious medical history of heart, lung, liver and kidney

         10. Provision of written informed consent prior to any study specific procedures

         11. Patients with good compliance

        Exclusion Criteria:

          1. Pregnant or lactating women (female patients of child-bearing potential must have a
             negative serum pregnancy test within 14 days of first day of drug dosing, or, if
             positive, a pregnancy ruled out by ultrasound)

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the course of the study

          3. Treatment with radiotherapy at the axial skeleton within 4 weeks before the first
             treatment or has not recovered from all toxicities of previously administered
             radiotherapy

          4. Treatment with an investigational product within 4 weeks before the first treatment

          5. Symptomatic central nervous system metastases, except for patients with stable and
             asymptomatic brain metastases who have completed a course of cranial irradiation, and
             have at least one measurable lesion outside the brain. Radiotherapy should be
             completed within 4 weeks prior to the registration

          6. Other active malignancies (including other hematologic malignancies) or other
             malignancies within the last 5 years, except for cured nonmelanoma skin cancer or
             cervical intraepithelial neoplasia.

          7. Patient having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          8. Uncontrolled serious infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <keyword>fine line chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

